| Active substance |
Peptide |
| Also known as |
NN2211 |
| Blood pressure |
May help reduce blood pressure in patients with type 2 diabetes |
| Chemical name |
Liraglutide |
| Dosage (medical) |
Typically initiated at 0.6 mg per day, titrated up to 1.2 mg or 1.8 mg depending on the patient's response and tolerability |
| Dosage (sports) |
Not applicable |
| Effects |
Improves glycemic control in type 2 diabetes, promotes weight loss |
| Formula |
C172H265N43O51 |
| Half-life |
Approximately 13 hours |
| Hepatotoxicity |
Low |
| Lab Test |
Monitoring of blood glucose and hemoglobin A1c levels |
| Main action |
Lowers blood glucose levels |
| Side effects |
Nausea, diarrhea, vomiting, constipation, reduced appetite, risk of pancreatitis |
| Storage conditions |
Store in a refrigerator (2В°C to 8В°C), protect from light, do not freeze |
| Substance class |
Glucagon-like peptide-1 (GLP-1) receptor agonist |
| Trade name |
Victoza, Saxenda |
| Use in sports |
Not typically used for performance enhancement |
| Water Retention |
Minimal |
| Active ingredient, mg |
15 |
| Release form |
Cartridge |
| Manufacturer |
SunSci Pharmaceutical |
